Want to see LQDA full AI Analyst Report?
LQDA Stock Chart & Stats
$70.49
$0.15(0.17%)
At close: 4:00 PM EDT
$70.49
$0.15(0.17%)
Day’s Range― - ―
52-Week Range$21.15 - $93.61
Previous CloseN/A
Volume722.63K
Average Volume (3M)2.05M
Market Cap
$6.31B
Enterprise Value$7.98K
Total Cash (Recent Filing)$284.18M
Total Debt (Recent Filing)$128.94M
Price to Earnings (P/E)45.5
Beta1.54
Next Earnings
Nov 10, 2026EPS Estimate
0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.57
Shares Outstanding89,508,890
10 Day Avg. Volume1,538,855
30 Day Avg. Volume2,045,880
Financial Highlights & Ratios
PEG Ratio0.83
Price to Book (P/B)66.33
Price to Sales (P/S)18.75
P/FCF Ratio-74.16
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$106.71Price Target Upside51.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)3.07
Revenue Forecast (FY)$739.43M
Bulls Say, Bears Say
Bulls Say
YUTREPIA Adoption And Revenue GrowthRapid prescription growth and strong patient starts indicate meaningful physician and patient adoption. Continued penetration of the inhaled prostacyclin market can provide a durable commercial base as Liquidia expands its specialty distribution and community reach.
Strong Profitability And LiquidityPositive earnings, operating leverage, and a growing cash balance strengthen Liquidia's ability to fund commercialization, clinical development, and potential legal obligations without relying as heavily on external capital.
Pipeline And Indication ExpansionThe pipeline provides avenues to extend the franchise beyond the current product and address dosing, safety, and additional indications. Multiple clinical programs could diversify future revenue and support longer-term growth if trials succeed.
Bears Say
Patent Litigation UncertaintyAn adverse litigation outcome could impose royalties, restrictions, or other remedies affecting YUTREPIA economics. The uncertainty may persist through the commercialization period and create a structural risk to margins and strategic flexibility.
Current Product Dosing BurdenFour-times-daily administration may reduce adherence and limit adoption among patients or prescribers prioritizing convenience. L606 could mitigate this issue, but it remains dependent on clinical and regulatory execution.
Rising Investment And Execution DemandsHigher R&D and SG&A spending is necessary to support the pipeline and commercial expansion, but it raises execution demands and could pressure cash conversion if revenue growth slows or development programs require more resources.
Liquidia Technologies News
LQDA FAQ
What was Liquidia Technologies Inc’s price range in the past 12 months?
Liquidia Technologies Inc lowest stock price was $21.14 and its highest was $93.61 in the past 12 months.
What is Liquidia Technologies Inc’s market cap?
Liquidia Technologies Inc’s market cap is $6.31B.
When is Liquidia Technologies Inc’s upcoming earnings report date?
Liquidia Technologies Inc’s upcoming earnings report date is Nov 10, 2026 which is in 75 days.
How were Liquidia Technologies Inc’s earnings last quarter?
Liquidia Technologies Inc released its earnings results on Aug 12, 2026. The company reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.758 by -$0.018.
Is Liquidia Technologies Inc overvalued?
According to Wall Street analysts Liquidia Technologies Inc’s price is currently Undervalued.
Does Liquidia Technologies Inc pay dividends?
Liquidia Technologies Inc does not currently pay dividends.
What is Liquidia Technologies Inc’s EPS estimate?
Liquidia Technologies Inc’s EPS estimate is 0.88.
How many shares outstanding does Liquidia Technologies Inc have?
Liquidia Technologies Inc has 89,508,890 shares outstanding.
What happened to Liquidia Technologies Inc’s price movement after its last earnings report?
Liquidia Technologies Inc reported an EPS of $0.74 in its last earnings report, missing expectations of $0.758. Following the earnings report the stock price went down -10.517%.
Which hedge fund is a major shareholder of Liquidia Technologies Inc?
Currently, no hedge funds are holding shares in LQDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Liquidia Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$106.71 (51.39% Upside)
$106.71 (51.39% Upside)
Blogger Sentiment
Bullish
LQDA Sentiment 85%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 285.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $122.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
359.35%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
102.76%
Trailing 12-Months
Company Description
Liquidia Technologies Inc
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
LQDA Company Deck
LQDA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum—robust quarter-over-quarter sales (+31%), substantial patient adoption (~5,000+ patients started) and improving profitability (net income ~$74.7M, adjusted EBITDA ~$96.3M) alongside a healthy cash build (~$284M). Clinical data and a progressing pipeline (10 studies, L606 Phase III enrollment) underpin future growth potential. Offsetting factors include a 4x daily dosing requirement for the current product, planned increases in R&D and SG&A (R&D expected to double in H2 2026), pending patent litigation that could create legal/royalty risk, and the need for further community penetration. On balance, the positive operational, financial, and clinical developments materially outweigh the manageable near-term risks.View all LQDA earnings summariesLQDA Stock 12 Month Forecast
Average Price Target
$106.71
▲(51.39% Upside)
Technical Analysis
Ocular Therapeutix
―
Adaptive Biotechnologies
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Recursion Pharmaceuticals
―
Ownership Overview
30.14% Insiders
8.40% Mutual Funds
37.54% Other Institutional Investors
5.60% Public Companies and Individual Investors